EIKON Group

https://www.eikon.group
https://www.linkedin.com/company/eikon-group/

EIKON Group is a privately owned UK-based company founded in 2014. Employing approximately 210 people, it provides broadcast professional services specializing in post-production, localization, and mastering. In 2023, the company's revenue was less than $25 million.

2023 Revenue

Founded

2014

Headcount

203

Headquarters

Primary Segment

Broadcast professional services

Ownership

Privately Owned

Deployments

News Summary:

Eikon secured $350.7 million in Series D funding in 2024. This was part of a larger trend of significant venture capital investment in biopharma companies that year, although the pace of such large deals slowed. Since its founding in 2019, Eikon raised over $1.1 billion in private funding to support its operations, including the development of EIK1001, a co-agonist of toll-like receptors 7 and 8. Information about the global tattoo supplies market is irrelevant to Eikon's activities.

Similar Companies

Subscribe for full access to EIKON Group's profile

EIKON Group offers 9 products in the media tech industry. EIKON Group's product portfolio comprises of production and post production, media cloud and storage, broadcast professional services and content supply chain.

Subscribe for full access to EIKON Group's products in full detail

EIKON Group's revenues were less than $25M in 2023. Caretta Research has split EIKON Group's revenue into 8 different product categories, the largest of which is localisation and access services. For full access to EIKON Group's revenue breakdown subscribe to Caretta Portal.

Subscribe for full access to EIKON Group's revenue in full detail

Mar

18th

2025

11:41

Financial Results, Regulatory and Legal, Caretta Research_Monitor Company

BUZZ-U.S. STOCKS ON THE MOVE- Tesla, Block, Alibaba Group

Eikon search string for individual stock moves: (STXBZ) The Day Ahead newsletter: here The Morning News Call newsletter: here March 18 (Reuters) - U.S. stock index futures struggled for direction on Tuesday ahead of the Federal Reserve’s upcoming meeting that will be closely monitored for commentary from the central bank on the potential economic ramifications of ongoing tariff disputes.

LongPort

Mar

15th

2025

06:00

Events, Caretta Research_Monitor Company

Eikon Exhibition Centre celebrates tenth anniversary by lending a helping hand at Lisburn Foodbank

In recent weeks, the Eikon Operations team was proud to be part of a project that holds deep importance for the Lisburn area, collaborating with the Lisburn Foodbank to enhance the services they provide to those in need in the local community.

Belfast News Letter

Mar

15th

2025

06:00

Events, Caretta Research_Monitor Company

Eikon Exhibition Centre celebrates tenth anniversary by lending a helping hand at Lisburn Foodbank

Watch more of our videos on ShotsTV.com and on Freeview 262 or Freely 565 Visit Shots! now As the Eikon Exhibition Centre celebrates a significant milestone – marking 10 years at its Halftown Road location in Lisburn – the venue plays a notable role in supporting the local community.

Northern Ireland World

Mar

12th

2025

07:29

Financial Results, Caretta Research_Monitor Company

Tattoo Accessories Market Innovations: Emerging Trends, Size, Share, and Future Growth by 2025 - 2032 | Infinite Irons, EZ Tattoo Supply, EIKON, Cheyenne - Professional Tattoo Equipment

Tattoo accessories market is estimated to be valued at USD 1,025.5 Mn in 2025 and is expected to reach USD 1,626.3 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

openPR

Mar

6th

2025

02:23

Financial Results, Business Expansion, Caretta Research_Monitor Company

Tattoo Supplies Market Size, Growth Analysis 2031 by Key Vendors- Mithra, Eikon Device, DragonHawk

USA, New Jersey: According to Verified Market Reports analysis, the global Tattoo Supplies Market size was valued at USD 2.7 Billion in 2023 and is projected to reach USD 4.6 Billion by 2031, growing at a CAGR of 7.1% from 2024 to 2031.

openPR

Mar

3rd

2025

18:30

Funding Activities

Finance Watch: Mega-Rounds Take A Breather After Giving Life To VC Funding In 2024

Private Company Edition: $100m-plus venture capital mega-rounds drove biopharma company fundraising closer to record-breaking levels in 2024, but the pace of big VC deals has slowed aside from Callio’s $187m series A, Eikon’s $350.7m series D and Enveda’s series C extension to $150m.

Citeline

Mar

3rd

2025

04:30

Funding Activities

Fierce Biotech Fundraising Tracker '25: Callio launches with $187M series A; Eikon's eye-catching $350M series D

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's tracker, which means including financing rounds north of $50 million.

Fierce Biotech

Feb

28th

2025

10:06

Funding Activities

Series D: Eikon banks $350.7m to advance cancer trials

Since its founding in 2019, California-based company Eikon has privately raised over $1.1 billion to fund its operations in developing and moving medicines through the clinic. The firm’s lead program, EIK1001, is a co-agonist of toll-like receptors 7 and 8.

Bioxconomy

Feb

27th

2025

20:34

Caretta Research_Monitor Company

Bluebird Fire Sale, Regeneron’s Gene Therapy for Deafness, & Eikon Raises a Bundle

Sorry, you have Javascript Disabled! To see this page as it is meant to appear, please enable your Javascript!

Timmerman Report

Feb

26th

2025

18:30

Funding Activities

Biotech Bounces Back: Eikon Therapeutics Secures Monumental Funding Amid Scientific Breakthroughs

Eikon Therapeutics secured $351 million in a Series D funding round, highlighting significant investor interest in biotech innovation. The company utilizes super-resolution microscopy to develop therapies for cancers such as breast, ovarian, prostate, and skin. With this funding, Eikon advances global clinical studies across 28 countries, supporting their ambitious research pipeline.

elblog.pl

Feb

26th

2025

18:30

Funding Activities

Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round

The company is moving its toll-like receptor 7/8 agonist into late-stage development for melanoma as it closes a $350.7m series D venture funding round.

Citeline

Feb

26th

2025

14:05

Funding Activities

Perlmutter's Eikon raises $351m in major financing round

Eikon Therapeutics has added to its already copious cash reserves with a $351 million fourth-round financing to fund a rapidly expanding clinical pipeline of cancer therapies. The startup – helmed by MSD's former head of R&D Roger Perlmutter – said that Series D has taken the total raised to more than $1.1 billion since it was formed in 2019.

Pharmaphorum

EIKON Group's customers primarily consist of entertainment Providers and consumer electronics companies. Examples of EIKON Group's customers include The Walt Disney Company, Paramount Global and Apple.

Analysis

Data

Analysis

Data

EIKON Group

2023 Revenue

Founded

Headcount

Headquarters

Primary Segment

Ownership

Deployments

News Summary:

Similar Companies

Example Customers

Analyst insight reports